Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans

Sponsor
University Hospital, Clermont-Ferrand
Study ID
NCT07177885
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 50 Years
Healthy Volunteers
Not accepted

Interventions

  • Blood collection — BIOLOGICAL
    Blood sampling. For patients who have had their cerebrospinal fluid sample taken as part of their treatment, a surplus sample will be used to perform the same measurements.

Study Details

Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.

Key Dates

First listed
Sep 17, 2025
Start date
Mar 5, 2026
Status verified
Mar 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
144 participants (estimated)

Arms

  • Arm: Migraineurs responding to triptans
    Blood collection
  • Arm: Migraine sufferers resistant to triptans
    Blood collection

Primary Outcome Measure

Plasma tryptophan levels [ Time Frame: Baseline ]

Central Contacts

Find similar trials

Nationwide
Migraine trialsNeurology trials

Related Studies